Order Article Reprints

Li W, Sparidans RW, Lebre MC, Beijnen JH, Schinkel AH. ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics. 2021; 13(11):1761. https://doi.org/10.3390/pharmaceutics13111761

Li, Wenlong, Rolf W. Sparidans, Maria C. Lebre, Jos H. Beijnen, and Alfred H. Schinkel. 2021. "ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability" Pharmaceutics 13, no. 11: 1761. https://doi.org/10.3390/pharmaceutics13111761

Li, W., Sparidans, R. W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2021). ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics, 13(11), 1761. https://doi.org/10.3390/pharmaceutics13111761